ThromboGenics plans to absorb Belgian subsidiary Thromb-X
25-May-2007
Thromb-X is based in Leuven, Belgium, and focuses on the research and development activities of the Group. This decision will enable ThomboGenics to streamline its corporate structure, consolidating its Belgian activities. There will be no impact on the company operations or financials.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.